An interventional study of rTMS real stimulation stage1 and rTMS shame stimulation stage1 in Parkinson's Disease, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment
Among 278 studies in Parkinson Disease with a site in China — 129 open to participants now, 136 under way, 3 of them phase 3. Parkinson Disease · China.
Among the 278 studies in Parkinson Disease with a site in China, this one is the 92nd largest by planned enrollment of the 210 interventional ones that give a count, is one of 30 that started in 2023, is one of 115 with no phase, reaches primary completion later than 51 of the 135 other live ones, and was the 143rd registered.
4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
This study's planned enrollment of 56 is above the median of 40 across 3,353 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →129 of the 278 studies in Parkinson Disease with a site in China are open now, in 12 countries. Each count lists the studies.
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 63 take children under 18; 189 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →278 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 30 started in 2023.
Median enrollment 48 across the 210 interventional studies, 215 across the 68 observational. Of the 95 that completed or were terminated, 19 (20%) have results posted.
63 of 278 have an industry lead sponsor. The 10 most frequent:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 182 studies on the registry; 108 are open to participants now.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
43 of the studies in Parkinson Disease with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725562Phase 3Zhejiang Vimgreen Pharmaceuticals, Ltd.VG081821AC Tablets for Early to Mid-stage Parkinson's Disease | 2027-10-01 |
| NCT07018388Ruijin HospitalIntrapatient Comparison of STN and GPi tTIS in PD | 2026-11-01 |
| NCT06090682Tianjin Huanhu HospitalEffect and Mechanism of Brain Stimulation for Parkinson's Disease With Cognitive Impairment | 2026-11-01 |
| NCT07028632iRegene Therapeutics Co., Ltd.The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease | 2026-12 |
| NCT07604116Synusight Biotech (Shanghai) Co., Ltd.A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA | 2026-12 |
Among the 278 studies in Parkinson Disease with a site in China, from their registry updates:
At present, no drug therapy has been proven to delay the progression of Parkinson's disease (PD). rTMS, as a non-invasive neuromodulation method, can regulate Slow-wave sleep (SWS). SWS is recognized closely related to neurodegeneration. However, there has been no clinical studies on if rTMS could delay the progression of PD by regulating SWS.
The main purpose of this study is to explore the changes of SWS in non-rapid eye movement (NREM) sleep period in PD patients by using rTMS, and the relationship with potential improvements of SWS and motor symptom delay. The study aims to find a potential new treatment strategy to delay the neurodegenerative process in PD patients by modulating SWS by rTMS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Those who are unwilling to participate in the study or unable to sign the form; and other circumstances that the researcher considers inappropriate to participate in the study.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
stage1+stage2 real stimulation
Device: rTMS real stimulation stage1 · Device: rTMS real stimulation stage 2
stage1 sham stimulation + stage2 real stimulation
Device: rTMS shame stimulation stage1 · Device: rTMS real stimulation stage 2
In the first stage, the early treatment group use low-frequency rTMS real stimulation,
In the first stage, the control group (delayed treatment group) all use sham stimulation.
In the second stage, both the early treatment group and the control group (delayed treatment group) will be treated with true stimulation low-frequency rTMS.
Change of Motor Function in PD by Low Frequency rTMS Stimulation
the score of Unified Parkinson's Disease Rating ScaleⅢ (UPDRSIII)\[off\] The higher the score, the more severe the motor dysfunction
Time frame: Day14
Effects of low-frequency rTMS stimulation on motor symptoms
the score of Unified Parkinson's Disease Rating ScaleⅢ (UPDRSIII) \[on\] The higher the score, the more severe the motor dysfunction
Time frame: Day28,Day56
Measurement of improved balance function in patients with Parkinson's disease
the score of Berg Balance Scale (BBS)\[0-56\] The higher the score, the better the balance
Time frame: Day14,Day28,Day56
Assessment of sleep structure in patients with Parkinson's disease
Use polysomnography (PSG) to record the proportion of slow-wave sleep
Time frame: Day14,Day28,Day56
Effects of low-frequency rTMS stimulation on anxiety
the score of Hamilton Anxiety Rating Scale（HAMA)\[0-64\] The higher the score, the more anxious
Time frame: Day14,Day28,Day56
Effects of low-frequency rTMS stimulation on cognition
the score of Montreal Cognitive Assessment（Moca)\[0-30\] The lower the score, the more severe the cognitive dysfunction
Time frame: Day14,Day28,Day56
Effects of low-frequency rTMS stimulation on cortical excitability
short-interval cortical inhibition(SICI)
Time frame: Day14,Day28
Effects of low-frequency rTMS stimulation on depression
the score of Hamilton Depression Rating Scale（HAMD） Total score ≥ 20 points: may be mild or moderate depression; The higher the score, the more depressed
Time frame: Day14,Day28,Day56
Assessment of daytime sleepiness in patients with Parkinson's disease
the score of The Epworth Sleeping Scale(ESS)\[0-24\] The higher the score, the more lethargic
Time frame: Day14,Day28,Day56
Effects of low-frequency rTMS stimulation on gait
Use a quantitative gait analysis system to analyze the change of gait
Time frame: Day14,Day28,Day56
Effects of low-frequency rTMS stimulation on brain connectivity in the PD brain
functional magnetic resonance imaging (fMRI) (Default mode network, DMN）
Time frame: Day0,Day14,Day28
Changes in salivary melatonin levels
salivary melatonin levels(Fasting)
Time frame: Day0,Day14,Day28,Day56
Started Sep 2023 (actual). Primary completion is estimated for Jul 2026, 34 months after the start.
Of 1,291 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 34 months is above that.
Counting every sponsor, half of 1,367 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine →